Helen Weston

PD23 Economic Evaluation Of Prophylactic Immunoglobulin Versus Prophylactic Antibiotics In Hematological Malignancies: Results From The RATIONAL Feasibility Trial

Sara Carrillo de Albornoz, Alisa M. Higgins, Dennis Petrie, Adam Irving et autres

Introduction Patients with hematological malignancies are at high risk of infections due to both the disease and the associated treatments. The use of immunoglobulin (Ig) to prevent infections is increasing in this population, but its cost effectiveness is unknown. This trial-based economic …

Initial Results from the Frailty-Stratified, Randomised Controlled Bayesian Adaptive Trial of Bortezomib Versus Lenalidomide in Transplant Ineligible Myeloma (TI-NDMM) - the FRAIL-M Study (AMaRC 19-01; ALLG MM22)

Sueh‐li Lim, John Reynolds, Lucy F. Pemberton, Tricia E. Wright et autres

Introduction Real-world survival for TI NDMM patients is significantly inferior compared to transplant eligible (TE)-NDMM patients, with data from the Australian and New Zealand Myeloma and Related Diseases Registry demonstrating median overall survival of 48 vs 68 months respectively (p <0.001; HR=2.3), …

au, nz (code pays fourni par la source)

Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for transplant-ineligible myeloma: AMaRC 03-16

Peter N. Mollee, John Reynolds, Wojciech Janowski, Hang Quach et autres

ABSTRACT: In newly diagnosed transplant-ineligible patients with myeloma, daratumumab has improved outcomes when added to the standard-of-care regimens. In a randomized trial, we tested whether similar improvements would be observed when daratumumab was added to the bortezomib, cyclophosphamide, and dexamethasone (VCD) regimen. …

au (code pays fourni par la source)

Immunoglobulin replacement vs prophylactic antibiotics for hypogammaglobulinemia secondary to hematological malignancy

Zoe McQuilten, Robert Weinkove, Lê Thị Phương Thảo, Philip J. Crispin et autres

ABSTRACT: Immunoglobulin replacement and prophylactic antibiotics are commonly used to prevent infections in patients with secondary hypogammaglobulinemia due to hematological malignancies but have never been directly compared. In this randomized controlled feasibility trial conducted in 7 hospitals in Australia and New Zealand, …

au, nz (code pays fourni par la source)

Economic evaluation: immunoglobulin vs prophylactic antibiotics in hypogammaglobulinemia and hematological malignancies

Sara Carrillo de Albornoz, Alisa M. Higgins, Dennis Petrie, Adam Irving et autres

ABSTRACT: Patients with hematological malignancies are at high risk of developing hypogammaglobulinemia (HGG) and infections. Immunoglobulin (Ig) is one recommended option to prevent these infections, but it is expensive, and its cost-effectiveness compared with other prevention strategies remains unknown. We conducted a …

au, nz (code pays fourni par la source)

Hypereosinophilic syndrome with cutaneous manifestations successfully treated with Dupilumab as a sole agent: A case report

Kayla Scully, Emily Ximin Shao, Leith A. Banney, Helen Weston

Hypereosinophilic syndrome describes a process in which eosinophils in the peripheral blood are persistently increased, with variable clinical manifestations. Finding efficacious treatments for this disease can be challenging. This case describes a 72-year-old man with idiopathic hypereosinophilic syndrome with cutaneous manifestations who …

au (code pays fourni par la source)

Germline Missense Variants in SH2B3 Underpin Platelet Count Variation and Inherited MPN

Liesl Butler, Christine U. Lee, Graham William Magor, Rhiannon Morris et autres

Background:BCR-ABL-negative MPNs arise from mutations that dysregulate JAK-STAT signalling. SH2B3 encodes LNK, a key negative regulator of this pathway [1]. Somatic loss of function mutations and missense variants in SH2B3 occur in MPNs [2]. Aim: To validate missense germline SH2B3 variants as …

au (code pays fourni par la source)

A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16)

Peter N. Mollee, John Reynolds, Wojciech Janowski, Hang Quach et autres

Abstract Introduction Daratumumab, when added to standard of care regimens in relapsed and untreated myeloma, has consistently demonstrated significant improvements in response rates, induction of MRD negative responses and prolonged progression-free survival (PFS) while proving highly tolerable with minor increases in overall …

au, gb (code pays fourni par la source)

Longitudinal study of intravenous versus subcutaneous immunoglobulin replacement therapy in hematological malignancy

Tanja M. Windegger, Janine English, Helen Weston, Karen Morwood et autres

AIM: To present findings from a longitudinal study on infection risk, mortality, and patient perspective of intravenous immunoglobulin (IVIg) and subcutaneous immunoglobulin (SCIg) treatment for patients with hypogammaglobulinemia secondary to hematological malignancy or its treatment (abbreviated as SID). METHODS: Observational study period …

au (code pays fourni par la source)

A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16)

Peter N. Mollee, John Reynolds, Wojciech Janowski, Hang Quach et autres

Introduction Daratumumab, when added to standard of care regimens in relapsed and untreated myeloma, has consistently demonstrated significant improvements in response rates, induction of MRD negative responses and progression-free survival (PFS) while proving highly tolerable with minor increases in overall regimen toxicity. …

au, gb (code pays fourni par la source)

Bortezomib use and outcomes for the treatment of multiple myeloma

Crystal Loke, Peter N. Mollee, Ian McPherson, Euan Thomas Walpole et autres

BACKGROUND: The public subsidy in Australia of bortezomib (Velcade) for untreated non-transplant multiple myeloma patients was based on the VISTA trial. AIMS: To ascertain the health outcomes of bortezomib in 'real world' transplant-ineligible elderly patients, compared to trial data. METHODS: Patient and …

au (code pays fourni par la source)

Subcutaneous immunoglobulin in patients with common variable immunodeficiency

Tanja M. Windegger, Karen Morwood, Helen Weston, Janine English et autres

Background: We have recently reported that primary and secondary immunodeficiency patients have different perspectives on the clinical and quality of life impact of immunoglobulin therapy (unpublished data). Purpose: This study compares the clinical efficacy of the first against the second year of …